Cocrystal Development Pipeline

Our development programs include a wide variety of serious and/or chronic viral diseases including influenza, COVID-19, hepatitis C and gastroenteritis caused by norovirus.

Program Discovery Preclinical Phase 1 Phase 2a Phase 2b Phase 3
Influenza A CC-42344 oral PB2 Inhibitor
Discovery Phase complete
Preclinical Phase complete
Phase 1 Phase complete
Phase 2a Phase complete
Phase 2b Phase complete
Phase 3 Phase complete
Influenza A/B

In collaboration with

Collaboration
Influenza A/B Inhibitor
Discovery Phase complete
Preclinical Phase complete
Phase 1 Phase complete
Phase 2a Phase complete
Phase 2b Phase complete
Phase 3 Phase complete
Influenza A CC-42344 Inhaled PB2 inhibitor
Discovery Phase complete
Preclinical Phase complete
Phase 1 Phase complete
Phase 2a Phase complete
Phase 2b Phase complete
Phase 3 Phase complete
COVID-19 CDI-988 Oral Protease Inhibitor
Discovery Phase complete
Preclinical Phase complete
Phase 1 Phase in progress
Phase 2a Phase not started
Phase 2b Phase not started
Phase 3 Phase not started
COVID-19 (Licensed) CDI-45205 Protease Inhibitor
Discovery Phase complete
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2a Phase not started
Phase 2b Phase not started
Phase 3 Phase not started
COVID-19 Replication Inhibitors
Discovery Phase in progress
Preclinical Phase not started
Phase 1 Phase not started
Phase 2a Phase not started
Phase 2b Phase not started
Phase 3 Phase not started
Norovirus Gastroenteritis CDI-988 Oral Protease Inhibitor
Discovery Phase complete
Preclinical Phase complete
Phase 1 Phase in progress
Phase 2a Phase not started
Phase 2b Phase not started
Phase 3 Phase not started